Merck Sprints Toward Late 2020 Filing For Pneumococcal Vaccine V114

Company Is Catching Up With Pfizer’s Planned Q4 Submission Of 20vPnC

 
• By Mandy Jackson
group of cyclist at professional race
Merck is racing ahead with a competitor to Prevnar 13 and Pfizer's 20-valent vaccine candidate • Source: Shutterstock

More from Clinical Trials

More from R&D